Guide/Experiment Planning for Freely Behaving Animals

From Miniscope
Jump to: navigation, search


Guide · 22 June 2026 21:00:00


Workflow

Prerequisites — complete these first:
(none — this is a starting node)
Next steps — these build on this guide:

Overview

This guide should be completed before any animals are ordered or surgeries are scheduled. The decisions made here determine your surgical timeline, cohort size, imaging approach, and whether your behavioral setup is ready to collect clean data on the day you need it.

Miniscope experiments have more upstream dependencies than standard behavioral studies — viral expression windows, surgical attrition, indicator optimization, and imaging quality checks all interact with your experimental timeline. Planning these in sequence, working backwards from your target experiment date, will save significant time and animal use.

The most important planning resource available to you is not this guide — it is the primary literature on calcium imaging in your behavioral paradigm. Before making any of the decisions described below, read at least five to ten papers that combine Miniscope imaging with the general class of behavior you are studying. How those experiments were designed, what viral constructs and dilutions were used, what attrition rates were observed, and what went wrong is the most reliable guide to planning your own.

This guide is part of the Freely Moving Behavior Workflow. Complete this step before scheduling any surgeries. Next step: Guide/Pre-Experiment Checklist, then Guide/Surgery and baseplating.

Step 1 — Review the Literature

For each paper relevant to your paradigm and brain region, extract the following information before moving on to any other planning step.

What to extract Why it matters
Animal numbers per group; how many were excluded post-imaging Real-world attrition rates for your specific brain region and behavioral paradigm
Cell yields and variability across animals Sets realistic expectations for how many cells you will actually analyze
Viral construct, serotype, titer, injection volume, and expression incubation period Expression timelines and efficiency vary widely by construct, serotype, region, and cell type — this drives your entire surgery schedule
Whether a viral dilution study was performed, and at what dilutions Optimal titer is not transferable between vector cores or cell types; you may need to run your own dilution study (see Step 3)
Behavioral apparatus, camera setup, and any tracking software used Lets you source compatible equipment and identify compatibility issues before your first implanted session
Any methodological notes, supplementary protocols, or correspondence addresses Methods sections and supplementary notes often contain the practical knowledge that determines whether an experiment works
How behavioral data was scored or tracked Ensures you have the right software installed and validated before your first session
Tip: Keep a dedicated column in your reference manager for "animal attrition reasons and rates" and a separate column for "viral construct details." Both directly inform your cohort size and surgical timeline. Attrition rates and expression kinetics vary substantially between brain regions, surgical approaches, and labs — numbers from your specific paradigm are more useful than general estimates.

Freely moving Miniscope experiments have been used across a wide range of behavioral paradigms. The specific demands of your paradigm — whether it involves social interaction, spatial navigation, fear conditioning, sleep, or operant tasks — will determine which aspects of this workflow need the most careful attention. A social interaction paradigm introduces challenges around cable entanglement between animals; a sleep experiment requires many hours of recording per session; a water maze is not compatible with current Miniscope hardware (scopes are not waterproof). These paradigm-specific considerations are not fully addressed in this general workflow guide — they are addressed in the literature for your field.

Step 2 — Select Your Calcium Indicator

The choice of genetically encoded calcium indicator (GECI) affects your expression timeline, signal quality, and the scientific questions you can answer. This decision should be made before viral ordering and confirmed against the published literature for your brain region and cell type.

Indicator variant

The GCaMP family is by far the most widely used indicator for Miniscope imaging. Variants differ in their kinetic properties and sensitivity:

Variant type Kinetic properties Best suited for
Fast (e.g. GCaMP6f, jGCaMP8f) Fast rise time; lower sensitivity to low-frequency events Cell populations with high tonic firing rates; when temporal precision matters
Medium (e.g. GCaMP6m, jGCaMP8m) Intermediate kinetics and sensitivity General use; good starting point for most brain regions
Slow (e.g. GCaMP6s, jGCaMP8s) Slower kinetics; greater sensitivity to sparse or low-frequency events Populations with sparse activity; deep brain regions where signal-to-noise is lower

For Miniscope imaging in deep brain regions, slower variants with larger dynamic range are generally preferable because light scattering through the GRIN lens reduces signal-to-noise, and the slower kinetics do not present a practical limitation at typical Miniscope frame rates (15–60 Hz).

Expression method

There are two main approaches to expressing GECIs in the brain. For most freely moving Miniscope experiments, viral expression via adeno-associated virus (AAV) is the standard approach.

Method Advantages Considerations
Viral expression (AAV) Cell-type and region-specific expression; flexible; widely used in combination with Cre lines for genetic targeting of specific populations Requires optimization of titer and dilution (see Step 3); expression increases over time — overexpression is a risk in chronic studies; expression may be limited to a few weeks at high titer
Transgenic mouse lines Stable, uniform expression across the lifespan; no expression window constraint; reduces variability across animals Expression level is generally lower than viral, which may be insufficient for Miniscope imaging in some brain regions — must be empirically tested; available lines are primarily excitatory pyramidal neurons, which are not abundant in many subcortical regions
For chronic imaging studies: Expression levels of GCaMP increase moderately over time with viral delivery, which can cause overexpression at later timepoints. If your experiment requires imaging across many weeks, either use transgenic lines or optimize your viral dilution specifically at the longest planned experimental timepoint, not just the earliest. Overexpression leads to nuclear filling of GCaMP, loss of dynamic calcium signals, and eventually cell death.

Serotype selection

Different AAV serotypes have different cell-type tropism and transduction efficiency. Serotypes such as AAV1, AAV5, AAV9, and AAVDJ are commonly used for Miniscope experiments. The appropriate serotype depends on your target cell type and brain region — consult published protocols and your vector core. Titers are not directly comparable across vector cores, as physical and infectious titer are measured differently at different facilities.

Step 3 — Conduct a Viral Dilution Study

This step must be completed before beginning surgeries on your experimental cohort. Skipping it is one of the most common causes of cohort-level imaging failure.

Optimal viral titer varies by brain region, cell type, virus serotype, and vector core. The correct dilution for your preparation cannot be assumed from published protocols using different constructs or different facilities. A dilution study must be run in your specific combination of virus, brain region, and mouse line before experimental animals are used.

What to test

Inject a range of dilutions — typically 1:2, 1:4, 1:8, 1:16, and 1:32 from a high-titer stock — into the target brain region in a small number of animals. Use injection volumes and coordinates identical to those planned for experimental subjects.

When to assess

  • For acute imaging studies (single session): assess expression at the planned experimental timepoint (typically 3–8 weeks post-injection)
  • For chronic imaging studies (multiple sessions over weeks): assess at the longest planned timepoint — expression will be higher at later timepoints, and the dilution that looks optimal at 4 weeks may produce overexpression at 8–12 weeks

What healthy expression looks like

Healthy GCaMP expression should show:

  • Nuclear exclusion — the GCaMP fluorescence fills the cytoplasm in a honeycomb pattern around a dark nucleus. Uniform filling of the entire cell body, including the nucleus, indicates overexpression and impending cell death
  • Moderate cell density — enough expressing cells to populate the FOV, but not so dense that individual cells cannot be distinguished
  • No evidence of autofluorescence (bright, static spots with no dynamic fluctuations), which indicates tissue damage or cell death

Dilution study decision

What you observe Action
Nuclear filling in a large proportion of cells at your planned timepoint Dilution is too high — test a lower dilution (or wait and check at a later timepoint if expression is otherwise healthy)
Very few cells expressing GCaMP; sparse FOV Dilution is too low — test a higher dilution
Nuclear exclusion, moderate density, dynamic activity visible on live imaging Proceed with this dilution for your experimental cohort
Autofluorescence only; no dynamic signals Likely tissue damage or failed expression — check lens placement and injection coordinates before proceeding
Tip: If you have access to a two-photon microscope or anesthetized miniscope check, you can verify expression and dynamic activity in a living animal before proceeding to GRIN lens implantation. This is the most informative check available before committing to an implant surgery.

Step 4 — Estimate Your Animal Numbers

Calcium imaging experiments have substantially higher attrition than standard behavioral studies. Budget for losses at each stage independently, not as a single aggregate number.

Sources of attrition

The figures below are general estimates. Consult papers in your specific brain region and paradigm for more accurate numbers — attrition varies considerably across labs, regions, and surgical approaches.

Attrition stage Typical loss rate Notes
Viral expression failure or overexpression 10–20% Poor titer, off-target injection, wrong serotype, or insufficient incubation time; overexpression risk increases with time in chronic studies
GRIN lens implant failure 10–15% Excessive bleeding, tissue damage, or poor FOV placement relative to expressing cells
Baseplate surgery failure 5–10% Cement failure, animal health issues post-surgery
Poor imaging signal at recording 10–20% FOV shift, low expression, motion artifact, or photobleaching; higher in deep brain regions
Animal health or exclusion criteria 5–10% Weight loss, infection, behavioral outliers

Calculating cohort size

If your power analysis requires N animals per group, plan to start with 2–3× N, particularly if you are new to the surgical workflow, working in a deep brain region, or using a viral construct you have not used before in your lab. These multipliers may seem large, but they reflect the real compounding of independent attrition rates across pipeline stages.

IACUC note: Consult your IACUC protocol before finalizing animal numbers. Imaging-specific attrition is distinct from the attrition rates used in standard behavioral studies and may require a specific justification in your protocol.

Step 5 — Select Your GRIN Lens and Imaging Probe

The choice of imaging probe determines what brain regions you can access and the tradeoff between FOV size and tissue damage. This decision is closely linked to your viral injection strategy, because the lens must be placed approximately 200–300 µm above the expressing cell population.

Probe type

Three probe types are used for in vivo calcium imaging. For freely moving Miniscope experiments recording from individual neurons, a GRIN lens is required.

Probe type What it enables Limitations
Optical cannula (fiber photometry) Bulk population signal in freely moving animals; least invasive; accessible from any depth No cellular resolution — cannot identify individual cells
Cortical window Large FOV; cellular resolution across a wide cortical area Limited to superficial cortical regions; not compatible with deep brain structures
GRIN lens Cellular resolution in both superficial and deep brain regions; compatible with Miniscope head-mounting Small FOV; larger diameter lenses cause more tissue damage; requires tissue aspiration for cortical approach

GRIN lens selection

Select the lens length to reach your target region while leaving at least 2 mm of lens above the skull for baseplate attachment. Select lens diameter based on the tradeoff between FOV size and invasiveness:

Diameter Best suited for Notes
1.8 mm or 1 mm Superficial subcortical regions (e.g. dorsal CA1, mPFC) Larger FOV; tissue aspiration required; higher tissue damage
0.6 mm or 0.5 mm Deep brain regions (e.g. NAc, VTA, IL, vCA1, hypothalamus) Less tissue damage; smaller FOV; aspiration optional depending on depth

See Guide/Surgery and baseplating for detailed lens selection guidance by brain region and implantation procedures.

Plan virus injection relative to lens placement: The focal plane of standard GRIN lenses sits approximately 200–300 µm below the bottom of the lens. To bring expressing neurons into focus, the bottom of the implanted lens should be positioned 200–300 µm above the GCaMP-expressing cell population. Factor this offset into your stereotaxic coordinates — the injection site and the lens implant site are not at the same DV coordinate. For GRIN lenses implanted at depth, it is also recommended to inject virus 200–250 µm lateral to the lens implant site to avoid direct tissue damage at the injection site occluding the FOV.

Step 6 — Identify and Source Behavioral Equipment

Different paradigms require different behavioral equipment, and not all equipment is compatible with tethered Miniscope recording without modification. Verify compatibility for your specific setup before your first implanted animal session.

Equipment compatibility checklist

Check
Apparatus dimensions allow for Miniscope cable tethering — sufficient overhead clearance, no sharp edges on the cable path, no enclosed areas the cable can snag on
Ambient lighting is appropriate — avoid wavelengths that overlap with GCaMP excitation (~470 nm) or emission (~530 nm); blue and green LED illumination in the behavioral arena is often problematic
Behavioral camera field of view covers the full arena and clearly resolves the animal at the frame rate required for your tracking metric
Tracking software is installed, licensed, and tested on a sample video from this apparatus
A commutator is available if the task involves significant rotational movement
All components have been tested together as a complete integrated system

For detailed setup requirements see Guide/Behavioral Setup.

Step 7 — Validate Your Behavioral Paradigm on Naive Animals

Before any implanted animal enters your behavioral apparatus, run naive (non-implanted) animals through the complete protocol. This step is not optional.

What to validate

Criterion
Animals can learn or perform the task within your planned timeframe
The behavioral camera captures clean, trackable video across the full session duration under your recording conditions
Your tracking software produces accurate, artifact-free output on this video
Session timing, reward delivery, and any automated components work reliably
The full data pipeline — from raw session file to analyzed behavioral metric — runs without errors
You have recorded baseline behavioral metrics (e.g. distance traveled, velocity, time in zone) that you can use later to verify that implanted animals are behaving normally
If any of these criteria are not met on naive animals, they will not be met on implanted animals either. Fix the behavioral setup completely before proceeding. Problems discovered after surgery waste irreplaceable animals and months of preparation time.

The naive animal baseline data collected here is also what you will use during habituation and recording to verify that implanted animals are behaving normally. Without this reference, the judgment on experiment day is subjective.

Step 8 — Plan Your Surgical Workflow

Before beginning surgeries on your experimental cohort, establish:

  • Who will perform each surgical step (virus injection, GRIN lens implant, baseplate surgery)
  • Your realistic surgical throughput — how many animals can be operated on per day or per week
  • Where the bottlenecks are — surgery itself, recovery monitoring, or imaging verification
  • How you will manage staggered surgery dates if your cohort is larger than can be operated in a single session

If you are new to Miniscope surgeries, or if it has been more than a few months since your last surgery, schedule practice surgeries before your experimental cohort. See Guide/Surgery and baseplating for the full protocol.

Step 9 — Build Your Timeline Working Backwards

Starting from your target experiment date, work backwards to determine when each stage must occur. The viral expression window is the critical constraint — confirm the appropriate incubation time for your specific construct, vector core, and target brain region before scheduling anything else. Expression timelines can range from 2–3 weeks for superficial cortical regions to 5–8 weeks or more for deep brain targets.

Example timeline (for AAV calcium indicators)

This is a representative timeline. Your specific construct, titer, injection volume, and target brain region will shift these dates. Confirm the appropriate expression window before scheduling.

Approximate timepoint Activity
Weeks before Week 1 Conduct viral dilution study (see Step 3); allow at least 3 weeks for expression assessment; assess at your planned experimental timepoint or longer
Week 1 Virus injection surgery (combined with GRIN lens implant in a single surgery if using small-diameter lens without aspiration; see Guide/Surgery and baseplating)
Weeks 3–5 Recovery; GRIN lens implant if done as a second surgery; wait for expression
Weeks 5–6 Check expression through GRIN lens under anesthesia; perform baseplate surgery once clear cell bodies and dynamic activity are confirmed
Weeks 6–7 Animal handling & habituation; behavioral apparatus acclimation (see Guide/Animal Handling & Habituation)
Week 7 Behavioral setup verification; focal plane and LED setup (see Guide/Behavioral Setup, Guide/Data Acquisition)
Week 8+ Begin experiment
Expression timelines vary. For cortical regions, distinct Ca2+ transients may be visible as early as 2 weeks post-injection. For deep brain regions, 5–6 weeks is more typical. Using the wrong expression window — too short or too long — is one of the most common causes of poor imaging yield. Do not attach the baseplate until you can verify clear cell bodies and dynamic fluorescence activity through the GRIN lens.

References

  1. Zhou ZC, Gordon-Fennell A, Piantadosi SC, Ji N, Smith SL, Bruchas MR, Stuber GD. (2023) Deep-brain optical recording of neural dynamics during behavior. Neuron 111(23):3716–3738. https://doi.org/10.1016/j.neuron.2023.09.006
  2. Chen S, Wang Z, Zhang D, Wang A, Chen L, Cheng H, Wu R. (2020) Miniature Fluorescence Microscopy for Imaging Brain Activity in Freely-Behaving Animals. Neuroscience Bulletin 36(10):1182–1190. https://doi.org/10.1007/s12264-020-00561-z
  3. Kingsbury L, Huang S, Wang J, Gu K, Golshani P, Wu YE, Hong W. (2019) Correlated Neural Activity and Encoding of Behavior Across Brains of Socially Interacting Individuals. Cell 178(2):429–446.e16. https://doi.org/10.1016/j.cell.2019.05.022
  4. Zhao P, Aharoni D, Golshani P. (2025) GRIN lens implantation strategies for in vivo calcium imaging using miniature microscopy. PLoS One 20(5):e0323256. https://doi.org/10.1371/journal.pone.0323256
  5. Malvaut S, Constantinescu V-S, Dehez H, Doric S, Saghatelyan A. (2020) Deciphering Brain Function by Miniaturized Fluorescence Microscopy in Freely Behaving Animals. Frontiers in Neuroscience 14:819. https://doi.org/10.3389/fnins.2020.00819